Sanofi Files Suit in U.S. to Defend Paten Rights on Lantus® and Lantus® Solostar®

(Thomson Reuters ONE) -


Sanofi Files Suit in U.S. to Defend Patent Rights on Lantus® and Lantus®
Solostar®


Paris, France - September 19, 2016 - Sanofi announced today that it filed a
patent infringement suit against Merck Sharp & Dohme Corp. ("Merck") on
September 16, 2016 in the United States District Court for the District of
Delaware. In its suit Sanofi alleges infringement of ten patents.

The suit was triggered by a notification received from Merck in early August, in
which Merck stated that it had filed an NDA (505(b)(2) New Drug Application)
with FDA for an insulin glargine drug product. Merck also stated that its NDA
included a paragraph IV certification challenging all of the ten Sanofi patents
listed in the FDA Orange Book for Sanofi's Lantus® and Lantus® SoloStar®
products.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi is organized into five
global business units: Diabetes and Cardiovascular, General Medicines and
Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in
Paris (EURONEXT: SAN) and in New York (NYSE: SNY).





Contacts:

Media Relations Investor Relations
Mai Tran George Grofik
Tel. : +33 (0)1 53 77 46 46 Tel.: +33 (0)1 53 77 45 45
mr(at)sanofi.com ir(at)sanofi.com



PDF Version:
http://hugin.info/152918/R/2042593/762605.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Sanofi via GlobeNewswire

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 19.09.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 495412
Anzahl Zeichen: 2145

contact information:
Town:

PARIS

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 277 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Sanofi Files Suit in U.S. to Defend Paten Rights on Lantus® and Lantus® Solostar®"
steht unter der journalistisch-redaktionellen Verantwortung von

Sanofi (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

New Epidemiological Data Provide Additional Safety Evidence for Lantus(R) ...

PARIS, FRANCE -- (Marketwire) -- 06/11/12 -- Sanofi (EURONEXT PARIS: SAN) (NYSE: SNY) today announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanent ...

Sanofi Announces Results of ORIGIN, the World's Longest and Largest Randomi ...

PARIS, FRANCE -- (Marketwire) -- 06/11/12 -- Sanofi (EURONEXT: SAN) (NYSE: SNY) announced today results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention), which showed that Lantus® (insulin glargine [rDNA] injec ...

Lyxumia(R) (lixisenatide) in Combination With Basal Insulin Plus Oral Anti-Diabe ...

PARIS, FRANCE -- (Marketwire) -- 06/09/12 -- Sanofi (EURONEXT: SAN) (NYSE: SNY) announced today data demonstrating Lyxumia®* (lixisenatide), a once-daily investigational GLP-1 agonist, in combination with basal insulin plus oral anti-diabetic agen ...

Alle Meldungen von Sanofi